Skip to main content
SpringerLink
Log in

Clinical Management of Patients with Hypertension and High Cardiovascular Risk

Main Results of an Italian Survey on Blood Pressure Control

  • Original Article
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

Abstract

Introduction

Hypertension management and control still represents a major clinical challenge for physicians, as well as for National Health Care Systems, since high blood pressure (BP) levels in treated uncontrolled outpatients are related to a persistently increased risk of cardiovascular (CV) events. The Italian Society of Hypertension (SIIA) has prompted several educational interventions for improving BP control in Italy.

Aim

To evaluate clinical attitudes and preferences of large community sample of both specialized physicians and general practitioners, included in an educational program, endorsed by SIIA and aimed at improving interventions for achieving better BP control in Italy.

Methods

A predefined questionnaire, which included a main body with 17 questions and 15 specific items (3–4 questions for each item), was anonymously administered to a large community sample of physicians who have practice in managing outpatients with hypertension and high CV risk profile. Both specialized physicians and general practitioners, distributed throughout the whole Italian territory, have been included in this educational program. Data were reported into a computerised spreadsheet and centrally analysed. Confidentiality of the data were guaranteed during each phase of the study.

Results

From a total of 64 questions, 557 physicians (478 male, mean age 54.2 ± 7.1 years, average age of medical activity 28.0 ± 8.1 years), among which 261 (46.9 %) specialised physicians and 296 (53.1 %) general practitioners, provided 60,713 answers to the survey questionnaire. Physicians devote time and effort for achieving the recommended BP targets (<140/90 and <130/80 mmHg in high risk subgroups), yet they reported a very high rate of BP control (about 70 %). Concomitant presence of diabetes, cardiac and renal organ damage (35–50 %), as well as comorbidities (20–35 %), is reported to be high and able to impact on antihypertensive treatment’s efficacy. Appropriate BP assessment is also viewed as a key tool for verifying effectiveness of a given drug therapy. Beyond non-pharmacological options, ACE inhibitors and ARBs were considered to most useful, effective and well tolerated options to start and maintain antihypertensive treatment, thus adding diuretics or calcium-channel blockers if needed. Direct renin inhibitors was considered to be effective in difficult to treat hypertension and to provide sustained antihypertensive efficacy.

Conclusions

With the well-known limitations of an observational, cross-sectional survey, in which a predefined questionnaire was administered to physicians rather than collecting data from medical databases, this study provides useful and updated information on attitudes and preferences, as well as on difficulties and troubles for physicians when managing outpatients with hypertension and high CV risk profile in Italy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.

    Article  PubMed  Google Scholar 

  2. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829–39.

    Article  PubMed  Google Scholar 

  3. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527–35.

    Article  CAS  PubMed  Google Scholar 

  4. Bramlage P, Bohm M, Volpe M, Khan BV, Paar WD, Tebbe U, et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J Clin Hypertens (Greenwich). 2010;12(9):666–77.

    Article  Google Scholar 

  5. Ignatius J. “RR 160/80” Scipione Riva-Rocci (1863–1937). Duodecim. 1993;109(17):1493–4.

    CAS  PubMed  Google Scholar 

  6. Prugger C, Keil U, Wellmann J, de Bacquer D, de Backer G, Ambrosio GB, et al. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey. J Hypertens. 2011;29(8):1641–8.

    Article  CAS  PubMed  Google Scholar 

  7. Chobanian AV. Shattuck Lecture. The hypertension paradox—more uncontrolled disease despite improved therapy. N Engl J Med. 2009;361(9):878–87.

    Article  CAS  PubMed  Google Scholar 

  8. Erdine S, Redon J, Bohm M, Ferri C, Kolloch R, Kreutz R, et al. Are physicians underestimating the challenges of hypertension management? Results from the Supporting Hypertension Awareness and Research Europe-wide (SHARE) survey. Eur J Prev Cardiol. 2013;20(5):786–92.

    Article  PubMed  Google Scholar 

  9. Volpe M, Rosei EA, Ambrosioni E, Cottone S, Cuspidi C, Borghi C, et al. 2012 consensus document of the Italian Society of Hypertension (SIIA): strategies to improve blood pressure control in Italy: from global cardiovascular risk stratification to combination therapy. High Blood Press Cardiovasc Prev. 2013;20(1):45–52.

    Article  CAS  PubMed  Google Scholar 

  10. Volpe M, Rosei EA, Ambrosioni E, Cottone S, Cuspidi C, Borghi C, et al. Renal artery denervation for treating resistant hypertension: definition of the disease, patient selection and description of the procedure. High Blood Press Cardiovasc Prev. 2012;19(4):237–44.

    Article  CAS  PubMed  Google Scholar 

  11. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25(9):1751–62.

    Article  CAS  PubMed  Google Scholar 

  12. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11):2121–58.

    Article  CAS  PubMed  Google Scholar 

  13. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.

    Article  CAS  PubMed  Google Scholar 

  14. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219.

    Google Scholar 

  15. Masoudi FA, Ponirakis A, Yeh RW, Maddox TM, Beachy J, Casale PN, et al. Cardiovascular Care Facts: A Report from the National Cardiovascular Data Registry - 2011. J Am Coll Cardiol. 2013. doi:10.1016/j.jacc.2013.05.099.

  16. de Simone G, Izzo R, Verdecchia P. Are Observational Studies More Informative Than Randomized Controlled Trials in Hypertension? Pro Side of the Argument. Hypertension. 2013.

  17. Mancia G. Assessing antihypertensive treatment by real life data. J Hypertens. 2012;30(1):46–7.

    Article  CAS  PubMed  Google Scholar 

  18. Volpe M, Tocci G, Bianchini F, De Rosa M, Fedozzi E, Covezzoli A, et al. Use of aliskiren in a ‘real-life’ model of hypertension management: analysis of national Web-based drug-monitoring system in Italy. J Hypertens. 2012;30(1):194–203.

    CAS  PubMed  Google Scholar 

  19. Tocci G, Aimo G, Caputo D, De Matteis C, Di Napoli T, Granatelli A, et al. An observational, prospective, open-label, multicentre evaluation of aliskiren in treated, uncontrolled patients: a real-life, long-term, follow-up, clinical practice in Italy. High Blood Press Cardiovasc Prev. 2012;19(2):73–83.

    Article  CAS  PubMed  Google Scholar 

  20. De Giusti M, Dito E, Pagliaro B, Burocchi S, Laurino FI, Tocci G, et al. A survey on blood pressure levels and hypertension control in a sample of the Italian general population. High Blood Press Cardiovasc Prev. 2012;19(3):129–35.

    PubMed  Google Scholar 

  21. Corrao G, Nicotra F, Parodi A, Zambon A, Heiman F, Merlino L, et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension. 2011;58(4):566–72.

    Google Scholar 

  22. Dallongeville J, Banegas JR, Tubach F, Guallar E, Borghi C, Backer GD, et al. Survey of physicians’ practices in the control of cardiovascular risk factors: the EURIKA study. Eur J Prev Cardiol. 2012;19(3):541–50.

    Article  PubMed  Google Scholar 

  23. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598–605.

    Article  CAS  PubMed  Google Scholar 

  24. Redon J, Erdine S, Bohm M, Ferri C, Kolloch R, Kreutz R, et al. Physician attitudes to blood pressure control: findings from the Supporting Hypertension Awareness and Research Europe-wide survey. J Hypertens. 2011;29(8):1633–40.

    Article  CAS  PubMed  Google Scholar 

  25. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462–536.

    PubMed  Google Scholar 

  26. Palmieri L, Panico S, Vanuzzo D, Ferrario M, Pilotto L, Sega R, et al. Evaluation of the global cardiovascular absolute risk: the Progetto CUORE individual score. Ann Ist Super Sanita. 2004;40(4):393–9.

    PubMed  Google Scholar 

  27. O’Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European society of hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31(9):1731–68.

    Google Scholar 

  28. De Filippis S, Cuomo I, Lionetto L, Janiri D, Simmaco M, Caloro M, et al. Intramuscular aripiprazole in the acute management of psychomotor agitation. Pharmacotherapy. 2013;33(6):603–14.

    Article  PubMed  Google Scholar 

  29. Volpe M, Tocci G, Trimarco B, Rosei EA, Borghi C, Ambrosioni E, et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens. 2007;25(7):1491–8.

    Article  CAS  PubMed  Google Scholar 

  30. Hartmann B, Weise H, Bassenge E. Quality assurance in Riva-Rocci blood pressure measurement: simultaneous sphygmomanometry with open and covered pressure display. Z Kardiol. 1988;77(8):537–42.

    CAS  PubMed  Google Scholar 

  31. Tocci G, Giovannelli F, Sciarretta S, Ferrucci A, Zito GB, Volpe M. Management of hypertension and stroke prevention: results of the Italian cardiologist survey. Int J Clin Pract. 2009;63(2):207–16.

    Article  CAS  PubMed  Google Scholar 

  32. Borghi C, Dormi A, D’Addato S, Gaddi A, Ambrosioni E. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. J Hypertens. 2004;22(9):1707–16.

    Article  CAS  PubMed  Google Scholar 

  33. Prandin MG, Cicero AF, Veronesi M, Cosentino E, Dormi A, Strocchi E, et al. Persistence on treatment and blood pressure control with different first-line antihypertensive treatments: a prospective evaluation. Clin Exp Hypertens. 2007;29(8):553–62.

    Article  CAS  PubMed  Google Scholar 

  34. Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens. 2010;28(7):1584–90.

    Article  CAS  PubMed  Google Scholar 

  35. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens. 2008;26(4):819–24.

    Article  CAS  PubMed  Google Scholar 

  36. Verpooten GA, Aerts A, Coen N, Vancayzeele S, Hermans C, Bowles J, et al. Antihypertensive effectiveness of aliskiren for the ‘real-world’ management of hypertension: multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study). Int J Clin Pract. 2011;65(1):54–63.

    Article  CAS  PubMed  Google Scholar 

  37. Zeymer U, Dechend R, Deeg E, Kaiser E, Senges J, Pittrow D, et al. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry. Int J Clin Pract. 2012;66(3):251–61.

    Article  CAS  PubMed  Google Scholar 

  38. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transpl. 2009;24(5):1663–71.

    Article  CAS  Google Scholar 

  39. McMurray JJ, Abraham WT, Dickstein K, Kober L, Massie BM, Krum H. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail. 2012;14(4):341–3.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

MV and CB has received research grants from Novartis, has served in international advisory boards of Daiichi Sankyo, Menarini, Malesci, Guidotti and Novartis Farma, and has lectured in symposia supported by several drug companies producing ACE Inhibitors, ARBs and direct renin inhibitors; GT has no conflict of interest to disclose.

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome “Sapienza”, Sant’Andrea Hospital, Via di Grottarossa 1035-39, 00189, Rome, Italy

    Giuliano Tocci & Massimo Volpe

  2. IRCCS Neuromed, Pozzilli, IS, Italy

    Giuliano Tocci & Massimo Volpe

  3. Chair of Internal Medicine, University of Bologna, Bologna, Italy

    Claudio Borghi

Authors
  1. Giuliano Tocci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudio Borghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Massimo Volpe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuliano Tocci.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tocci, G., Borghi, C. & Volpe, M. Clinical Management of Patients with Hypertension and High Cardiovascular Risk. High Blood Press Cardiovasc Prev 21, 107–117 (2014). https://doi.org/10.1007/s40292-013-0028-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40292-013-0028-x

Keywords

Search

Navigation